{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Abstract\n",
    "The objective of this notebook will be to perform keyword analysis on the papers for Covid-19 risk factors."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import glob\n",
    "import json\n",
    "from os import path\n",
    "import pandas as np\n",
    "import pandas as pd\n",
    "from datetime import datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "papers_df = pd.read_csv('../output/papers_df.csv', \n",
    "                        index_col=0, \n",
    "                        keep_default_na=False,\n",
    "                       parse_dates=['publish_time'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "transmission_keywords = ['transmi', 'sneez', 'contact trac', 'reproduc', 'environ']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "smoke_keywords = ['smok']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "covid_keywords = ['COVID-19', 'HCoV-19', 'CORD-19' ,'2019-nCoV', 'Wuhan coronavirus', 'SARS-CoV-2', 'SARS-COV-2']\n",
    "covid_keywords = [word.lower() for word in covid_keywords]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# covid_papers = papers_df[papers_df['text_body'].apply(lambda x : \n",
    "#                                                 any(key in x.lower() for\n",
    "#                                                     key in covid_keywords)\n",
    "#                                                )]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_files = glob.glob(f'../data/**/*.json', recursive=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "paper_dicts = []\n",
    "for file in json_files:\n",
    "    name = path.basename(file)\n",
    "    with open(file) as f:\n",
    "        data = json.load(f)\n",
    "    paper_obj = {'id':name,\n",
    "                 'data':data}\n",
    "    paper_dicts.append(paper_obj)    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenize(text):\n",
    "    text = text.lower().strip()\n",
    "    if len(text) == 0:\n",
    "        return ''\n",
    "    if text[-1] == 's':\n",
    "        text = text[:-1]\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [],
   "source": [
    "sections = {}\n",
    "for paper in paper_dicts:\n",
    "    body = paper['data']['body_text']\n",
    "    paper_sections = set()\n",
    "    for paragraph in body:\n",
    "        if 'section' in paragraph:\n",
    "            paper_sections.add(paragraph['section'])\n",
    "    for section in paper_sections:\n",
    "        section = tokenize(section)\n",
    "        if section in sections:\n",
    "            sections[section] += 1\n",
    "        else:\n",
    "            sections[section] = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('introduction', 27243),\n",
       " ('discussion', 23709),\n",
       " ('conclusion', 14315),\n",
       " ('', 11781),\n",
       " ('result', 7043),\n",
       " ('statistical analysi', 4409),\n",
       " ('background', 4070),\n",
       " ('materials and method', 2475),\n",
       " ('method', 2447),\n",
       " ('1. introduction', 1410),\n",
       " ('statistical analysis ::: materials and method', 1268),\n",
       " ('results and discussion', 1252),\n",
       " ('competing interest', 1242),\n",
       " ('author contribution', 1134),\n",
       " ('summary', 1081),\n",
       " ('ethics statement', 1076),\n",
       " ('concluding remark', 860),\n",
       " ('statistical analysis ::: method', 844),\n",
       " ('funding', 818),\n",
       " (\"authors' contribution\", 792),\n",
       " ('acknowledgment', 682),\n",
       " ('data analysi', 674),\n",
       " ('statistical analyse', 631),\n",
       " ('conflict of interest', 605),\n",
       " ('conflicts of interest', 546),\n",
       " ('4. discussion', 540),\n",
       " ('ethics statement ::: materials and method', 536),\n",
       " ('conflict of interest statement', 532),\n",
       " ('study design', 506),\n",
       " ('statistic', 489),\n",
       " ('animal', 483),\n",
       " ('western blot analysi', 469),\n",
       " ('data collection', 455),\n",
       " ('diagnosi', 451),\n",
       " ('treatment', 448),\n",
       " ('abbreviation', 441),\n",
       " ('supplementary material', 440),\n",
       " ('cells and viruse', 424),\n",
       " ('viruse', 413),\n",
       " ('the study', 403),\n",
       " ('5. conclusion', 400),\n",
       " ('limitation', 395),\n",
       " ('flow cytometry', 392),\n",
       " ('authors’ contribution', 391),\n",
       " ('cell culture', 382),\n",
       " ('study population', 381),\n",
       " ('supporting information', 360),\n",
       " ('epidemiology', 357),\n",
       " ('phylogenetic analysi', 318),\n",
       " ('western blotting', 311),\n",
       " ('discussion and conclusion', 299),\n",
       " ('declaration of competing interest', 295),\n",
       " ('data availability', 291),\n",
       " ('author summary', 290),\n",
       " ('material', 290),\n",
       " ('ethical approval', 281),\n",
       " ('sample collection', 276),\n",
       " ('pre-publication history', 276),\n",
       " ('mice', 275),\n",
       " ('viru', 269),\n",
       " ('elisa', 268),\n",
       " ('objective', 265),\n",
       " ('additional information', 263),\n",
       " ('case report', 259),\n",
       " ('western blot', 251),\n",
       " ('a b s t r a c t', 236),\n",
       " ('patient', 234),\n",
       " ('electron microscopy', 234),\n",
       " ('statistical method', 229),\n",
       " ('additional file', 227),\n",
       " ('experimental design', 225),\n",
       " ('ethics statement ::: method', 222),\n",
       " ('antibodie', 219),\n",
       " ('prevention', 219),\n",
       " ('definition', 217),\n",
       " ('4. conclusion', 217),\n",
       " ('i. introduction', 213),\n",
       " ('data', 210),\n",
       " ('plasmid', 208),\n",
       " ('2.', 207),\n",
       " ('cell', 200),\n",
       " ('data analysis ::: method', 200),\n",
       " ('plasmid construction', 199),\n",
       " ('declaration of interest', 197),\n",
       " ('pathogenesi', 197),\n",
       " ('material and method', 194),\n",
       " ('conflict of interest statement ::: author contribution', 192),\n",
       " ('virus isolation', 191),\n",
       " ('sequence analysi', 191),\n",
       " ('clinical sign', 189),\n",
       " ('data source', 186),\n",
       " ('main', 186),\n",
       " ('immunohistochemistry', 185),\n",
       " ('rna extraction', 183),\n",
       " ('future direction', 182),\n",
       " ('participant', 179),\n",
       " ('supplementary data', 179),\n",
       " ('(which was not peer-reviewed)', 178),\n",
       " ('perspective', 177),\n",
       " ('ethical consideration', 173),\n",
       " ('cells and viru', 173),\n",
       " ('western blot analysis ::: materials and method', 171),\n",
       " ('acknowledgement', 169),\n",
       " ('statistical analyses ::: materials and method', 169),\n",
       " ('clinical feature', 168),\n",
       " ('sample', 164),\n",
       " ('histopathology', 162),\n",
       " ('future perspective', 160),\n",
       " ('influenza', 159),\n",
       " ('immunofluorescence', 158),\n",
       " ('contributor', 157),\n",
       " ('flow cytometry ::: materials and method', 155),\n",
       " ('reagent', 154),\n",
       " ('review', 153),\n",
       " ('outcome', 152),\n",
       " ('serology', 152),\n",
       " ('accession number', 152),\n",
       " ('cytotoxicity assay', 152),\n",
       " ('differential diagnosi', 152),\n",
       " ('experimental procedure', 149),\n",
       " ('data availability statement', 148),\n",
       " ('disclosure', 148),\n",
       " ('conclusions and perspective', 147),\n",
       " ('article in pres', 146),\n",
       " ('conflicts of interest:', 145),\n",
       " ('cell culture ::: materials and method', 145),\n",
       " ('ethic', 144),\n",
       " ('vaccine', 143),\n",
       " ('viruses and cell', 143),\n",
       " ('supplemental material', 142),\n",
       " ('statistical analyses ::: method', 142),\n",
       " ('animals ::: materials and method', 140),\n",
       " ('study design ::: method', 139),\n",
       " ('western blotting ::: materials and method', 138),\n",
       " ('data collection ::: method', 137),\n",
       " ('role of the funding source', 135),\n",
       " ('cells and viruses ::: materials and method', 135),\n",
       " ('subject', 134),\n",
       " ('cell viability assay', 134),\n",
       " ('analysi', 132),\n",
       " ('viral infection', 131),\n",
       " ('procedure', 129),\n",
       " ('statistics ::: materials and method', 129),\n",
       " ('cell line', 127),\n",
       " ('plaque assay', 126),\n",
       " ('etiology', 125),\n",
       " ('vaccination', 125),\n",
       " ('bacteria', 124),\n",
       " ('introducción', 123),\n",
       " ('contents lists available at sciencedirect', 122),\n",
       " ('a b', 121),\n",
       " ('protein expression and purification', 121),\n",
       " ('chemistry', 121),\n",
       " ('virus and cell', 120),\n",
       " ('data analysis ::: materials and method', 120),\n",
       " ('4.', 119),\n",
       " ('virus titration', 119),\n",
       " ('5.', 118),\n",
       " ('compliance with ethical standard', 118),\n",
       " ('clinical presentation', 118),\n",
       " ('prognosi', 118),\n",
       " ('management', 117),\n",
       " ('table 2', 117),\n",
       " ('immunofluorescence assay', 115),\n",
       " ('sensitivity analysi', 115),\n",
       " ('histology', 115),\n",
       " ('nucleotide sequence accession number', 112),\n",
       " ('disclaimer', 111),\n",
       " ('3.', 111),\n",
       " ('patients and method', 111),\n",
       " ('methodology', 110),\n",
       " ('rt-pcr', 110),\n",
       " ('patient characteristic', 107),\n",
       " ('finding', 106),\n",
       " ('clinical manifestation', 106),\n",
       " ('case presentation', 106),\n",
       " ('adenoviru', 106),\n",
       " ('elisa ::: materials and method', 105),\n",
       " ('real-time pcr', 104),\n",
       " ('literature review', 104),\n",
       " ('enzyme-linked immunosorbent assay (elisa)', 104),\n",
       " ('reference', 103),\n",
       " ('tuberculosi', 103),\n",
       " ('1.', 102),\n",
       " ('conclusions and future perspective', 101),\n",
       " ('abstract', 100),\n",
       " ('sampling', 100),\n",
       " ('3. discussion', 100),\n",
       " ('confocal microscopy', 99),\n",
       " ('transmission', 99),\n",
       " ('limitations ::: discussion', 98),\n",
       " ('phylogenetic analysis ::: materials and method', 98),\n",
       " ('pathology', 97),\n",
       " ('bacterial infection', 97),\n",
       " ('fig. 2.', 97),\n",
       " ('setting', 96),\n",
       " ('rotaviru', 95),\n",
       " ('nucleic acid extraction', 95),\n",
       " ('summary and conclusion', 95),\n",
       " ('respiratory syncytial viru', 95),\n",
       " ('6. conclusion', 95),\n",
       " ('sample collection ::: materials and method', 95),\n",
       " ('recommendation', 93),\n",
       " ('viruses ::: materials and method', 93),\n",
       " ('immunoblotting', 92),\n",
       " ('mice ::: materials and method', 92),\n",
       " ('pathophysiology', 91),\n",
       " ('•', 90),\n",
       " ('study population ::: method', 90),\n",
       " ('plasmids ::: materials and method', 90),\n",
       " ('figure 2', 89),\n",
       " ('key point', 89),\n",
       " ('chemical', 89),\n",
       " ('quantitative real-time pcr', 89),\n",
       " ('highlight', 89),\n",
       " ('search strategy', 87),\n",
       " ('search strategy and selection criteria', 87),\n",
       " ('influenza viru', 87),\n",
       " ('statistics ::: method', 87),\n",
       " ('3. result', 87),\n",
       " ('transmission electron microscopy', 86),\n",
       " ('figure 2.', 86),\n",
       " ('virus infection', 86),\n",
       " ('coronaviruse', 86),\n",
       " ('immunofluorescence microscopy', 86),\n",
       " ('model', 85),\n",
       " ('primer', 85),\n",
       " ('statistical analysis ::: material and method', 85),\n",
       " ('conclusions and future direction', 84),\n",
       " ('availability of data and material', 84),\n",
       " ('coronaviru', 84),\n",
       " ('sample preparation', 83),\n",
       " ('neutralization assay', 83),\n",
       " ('infectious disease', 83),\n",
       " ('malaria', 82),\n",
       " ('clinical sample', 81),\n",
       " ('ethical statement', 79),\n",
       " ('table 1', 79),\n",
       " ('real-time rt-pcr', 78),\n",
       " ('antibodies ::: materials and method', 78),\n",
       " ('consent for publication', 77),\n",
       " ('luciferase assay', 77),\n",
       " ('cells ::: materials and method', 77),\n",
       " ('phylogenetic analyse', 76),\n",
       " ('study design and participant', 76),\n",
       " ('disclosure of potential conflicts of interest', 76),\n",
       " ('case description', 76),\n",
       " ('microbiology', 76),\n",
       " ('compound', 75),\n",
       " ('cell culture and transfection', 75),\n",
       " ('risk factor', 75),\n",
       " ('participants ::: method', 75),\n",
       " ('intervention', 74),\n",
       " ('sequencing', 74),\n",
       " ('note', 74),\n",
       " ('measure', 74),\n",
       " ('supplemental information', 74),\n",
       " ('clinical specimen', 74),\n",
       " ('experimental animal', 74),\n",
       " ('western blot ::: materials and method', 74),\n",
       " ('flow cytometry analysi', 73),\n",
       " ('immunization', 73),\n",
       " ('expert commentary', 73),\n",
       " ('five-year view', 73),\n",
       " ('materials ::: materials and method', 73),\n",
       " ('antiviral activity', 72),\n",
       " ('animals ::: method', 72),\n",
       " ('added value of this study', 71),\n",
       " ('infection', 71),\n",
       " ('history', 70),\n",
       " ('statistical analysis. ::: materials and method', 70),\n",
       " ('funding source', 69),\n",
       " ('conclusion and perspective', 69),\n",
       " ('open acces', 69),\n",
       " ('laboratory diagnosi', 69),\n",
       " ('keyword', 68),\n",
       " ('other viruse', 68),\n",
       " ('parasite', 68),\n",
       " ('therapy', 68),\n",
       " ('statistical methods ::: method', 68),\n",
       " ('electron microscopy ::: materials and method', 68),\n",
       " ('study design ::: materials and method', 68),\n",
       " ('conflicto de interese', 68),\n",
       " ('animal experiment', 67),\n",
       " ('challenge', 67),\n",
       " ('design', 67),\n",
       " ('virology', 67),\n",
       " ('general', 67),\n",
       " ('key issue', 67),\n",
       " ('ethics approval and consent to participate', 66),\n",
       " ('case definition', 66),\n",
       " ('control', 66),\n",
       " ('figure 1.', 66),\n",
       " ('11', 65),\n",
       " ('laboratory method', 65),\n",
       " ('table 3', 65),\n",
       " ('ethics ::: method', 65),\n",
       " ('5', 64),\n",
       " ('implications of all the available evidence', 64),\n",
       " ('list of abbreviation', 63),\n",
       " ('study limitation', 63),\n",
       " ('research in context', 62),\n",
       " ('clinical finding', 62),\n",
       " ('statistical analysis.', 62),\n",
       " ('strengths and limitation', 62),\n",
       " ('west nile viru', 62),\n",
       " ('diagnostic', 62),\n",
       " ('human immunodeficiency viru', 62),\n",
       " ('western blot analysis ::: method', 62),\n",
       " ('results:', 61),\n",
       " ('figure 3', 61),\n",
       " ('primer design', 61),\n",
       " ('data availability ::: method', 61),\n",
       " ('neoplasia', 61),\n",
       " ('conclusion:', 60),\n",
       " ('in brief', 60),\n",
       " ('study participant', 60),\n",
       " ('histopathology and immunohistochemistry', 60),\n",
       " ('overview', 59),\n",
       " ('demographic', 59),\n",
       " ('study area', 59),\n",
       " ('construction of plasmid', 59),\n",
       " ('flow cytometric analysi', 59),\n",
       " ('immunofluorescence assay (ifa)', 59),\n",
       " ('antibiotic', 59),\n",
       " ('physical examination', 59),\n",
       " ('conflict of interest ::: author contribution', 59),\n",
       " ('sar', 58),\n",
       " ('animal model', 58),\n",
       " ('virus detection', 58),\n",
       " ('enzyme-linked immunosorbent assay', 58),\n",
       " ('specimen', 58),\n",
       " ('phylogenetic analysis ::: result', 58),\n",
       " ('rna extraction ::: materials and method', 58),\n",
       " ('7.', 57),\n",
       " ('specimen collection', 57),\n",
       " ('star+method', 57),\n",
       " ('key message', 57),\n",
       " ('interferon', 57),\n",
       " ('fungi', 57),\n",
       " ('analysis ::: method', 57),\n",
       " ('immunofluorescence ::: materials and method', 57),\n",
       " ('flow cytometry ::: method', 57),\n",
       " ('disclosure statement', 56),\n",
       " ('dna extraction', 56),\n",
       " ('outlook', 56),\n",
       " ('western blotting analysi', 56),\n",
       " ('sequence analysis ::: materials and method', 56),\n",
       " ('patient characteristics ::: result', 56),\n",
       " ('the model', 55),\n",
       " ('clinical characteristic', 55),\n",
       " ('laboratory testing', 55),\n",
       " ('indirect immunofluorescence assay', 55),\n",
       " ('antiviral assay', 55),\n",
       " ('prevention and control', 55),\n",
       " ('data ::: method', 55),\n",
       " ('western blotting ::: method', 55),\n",
       " ('study population ::: materials and method', 55),\n",
       " ('quantification and statistical analysi', 54),\n",
       " ('implementation', 54),\n",
       " ('mass spectrometry', 54),\n",
       " ('complication', 54),\n",
       " ('experimental', 54),\n",
       " ('antibodies and reagent', 54),\n",
       " ('influenza viruse', 54),\n",
       " ('6.', 54),\n",
       " ('cytomegaloviru', 54),\n",
       " ('7. conclusion', 54),\n",
       " ('reagents ::: materials and method', 54),\n",
       " ('3', 53),\n",
       " ('peptide synthesi', 53),\n",
       " ('other', 53),\n",
       " ('questionnaire', 53),\n",
       " ('editorial', 53),\n",
       " ('transfection', 53),\n",
       " ('cells and viruses ::: method', 53),\n",
       " ('4', 52),\n",
       " ('data extraction', 52),\n",
       " ('sample collection ::: method', 52),\n",
       " ('microscopy', 51),\n",
       " ('ethics approval', 51),\n",
       " ('measle', 51),\n",
       " ('rabie', 51),\n",
       " ('recombination analysi', 51),\n",
       " ('plant material', 51),\n",
       " ('rna interference', 51),\n",
       " ('10', 50),\n",
       " ('methods:', 50),\n",
       " ('quantitative rt-pcr', 50),\n",
       " ('immunoprecipitation', 50),\n",
       " ('study subject', 50),\n",
       " ('herpes simplex viru', 50),\n",
       " ('severe acute respiratory syndrome', 50),\n",
       " ('study population ::: result', 50),\n",
       " ('conclusions ::: discussion', 50),\n",
       " ('plasmid construction ::: materials and method', 50),\n",
       " ('tratamiento', 50),\n",
       " ('indirect immunofluorescence assay (ifa)', 49),\n",
       " ('human metapneumoviru', 49),\n",
       " ('escherichia coli', 49),\n",
       " ('mtt assay', 49),\n",
       " ('northern blot analysi', 49),\n",
       " ('rhinoviru', 49),\n",
       " ('confl icts of interest', 49),\n",
       " ('availability and requirement', 48),\n",
       " ('case 2', 48),\n",
       " ('transparency declaration', 48),\n",
       " ('dna sequencing', 48),\n",
       " ('virus strain', 48),\n",
       " ('clinical observation', 48),\n",
       " ('cells and virus ::: materials and method', 48),\n",
       " ('gene', 47),\n",
       " ('consent', 47),\n",
       " ('sample size', 47),\n",
       " ('future prospect', 47),\n",
       " ('elispot assay', 47),\n",
       " ('ribavirin', 47),\n",
       " ('adenoviruse', 47),\n",
       " ('viral disease', 47),\n",
       " ('cell viability assay ::: materials and method', 47),\n",
       " ('experimental design ::: materials and method', 47),\n",
       " ('9', 46),\n",
       " ('conclusions:', 46),\n",
       " ('quantitative pcr', 46),\n",
       " ('immunofluorescence staining', 46),\n",
       " ('outcome measure', 46),\n",
       " ('study site', 46),\n",
       " ('microarray analysi', 46),\n",
       " ('safety', 46),\n",
       " ('pcr', 46),\n",
       " ('bioinformatics analysi', 46),\n",
       " ('conclusions and outlook', 46),\n",
       " ('pneumonia', 46),\n",
       " ('immunohistochemistry ::: materials and method', 46),\n",
       " ('ethical considerations ::: method', 46),\n",
       " ('ethical approval ::: materials and method', 46),\n",
       " ('table 4', 46),\n",
       " ('data sharing', 45),\n",
       " ('study selection', 45),\n",
       " ('fluorescence microscopy', 45),\n",
       " ('transmission electron microscopy (tem)', 45),\n",
       " ('measurement', 45),\n",
       " ('instrument', 45),\n",
       " ('cancer', 45),\n",
       " ('fungal infection', 45),\n",
       " ('classification', 45),\n",
       " ('protozoa', 45),\n",
       " ('viruses and cells ::: materials and method', 45),\n",
       " ('mice ::: method', 45),\n",
       " ('inclusion and exclusion criteria', 44),\n",
       " ('case', 44),\n",
       " ('figure 4', 44),\n",
       " ('implication', 44),\n",
       " ('dear editor,', 44),\n",
       " ('noroviru', 44),\n",
       " ('confocal microscopy ::: materials and method', 44),\n",
       " ('figure 1', 43),\n",
       " ('laboratory finding', 43),\n",
       " ('supplementary information', 43),\n",
       " ('molecular docking', 43),\n",
       " ('inclusion criteria', 43),\n",
       " ('luciferase reporter assay', 43),\n",
       " ('plasmid construct', 43),\n",
       " ('miscellaneou', 43),\n",
       " ('clostridium difficile', 43),\n",
       " ('polymerase chain reaction', 43),\n",
       " ('patients ::: method', 43),\n",
       " ('6', 42),\n",
       " ('7', 42),\n",
       " ('site-directed mutagenesi', 42),\n",
       " ('elisa assay', 42),\n",
       " ('bioinformatic', 42),\n",
       " ('additional material', 42),\n",
       " ('dna vaccine', 42),\n",
       " ('conclusion and future direction', 42),\n",
       " ('immunofluorescence analysi', 42),\n",
       " ('indirect immunofluorescence', 42),\n",
       " ('data collection and analysi', 42),\n",
       " ('surveillance', 42),\n",
       " ('corticosteroid', 42),\n",
       " ('staphylococcus aureu', 42),\n",
       " ('19', 41),\n",
       " ('interpretation', 41),\n",
       " ('simulation', 41),\n",
       " ('reagents and antibodie', 41),\n",
       " ('infection control', 41),\n",
       " ('immunoblot analysi', 41),\n",
       " ('glossary', 41),\n",
       " ('conclusion and future perspective', 41),\n",
       " ('plaque reduction assay', 41),\n",
       " ('hepatitis b', 41),\n",
       " ('ethical approval ::: method', 41),\n",
       " ('image analysi', 40),\n",
       " ('patients and sample', 40),\n",
       " ('herpesviruse', 40),\n",
       " ('monoclonal antibodie', 40),\n",
       " ('outstanding question', 40),\n",
       " ('data sources ::: method', 40),\n",
       " ('patients ::: materials and method', 40),\n",
       " ('data collection ::: materials and method', 40),\n",
       " ('protein expression and purification ::: materials and method', 40),\n",
       " ('conclusione', 40),\n",
       " ('15', 39),\n",
       " ('introduction:', 39),\n",
       " ('exclusion criteria', 39),\n",
       " ('crystallization', 39),\n",
       " ('specificity', 39),\n",
       " ('| statistical analysi', 39),\n",
       " ('virus neutralization assay', 39),\n",
       " ('rna extraction and cdna synthesi', 39),\n",
       " ('necropsy', 39),\n",
       " ('declarations of interest', 39),\n",
       " ('application', 39),\n",
       " ('cell lines ::: materials and method', 39),\n",
       " ('real-time pcr ::: materials and method', 39),\n",
       " ('conclusion ::: discussion', 39),\n",
       " ('general consideration', 39),\n",
       " ('further reading', 39),\n",
       " ('1', 38),\n",
       " ('communication', 38),\n",
       " ('serum sample', 38),\n",
       " ('experimental infection', 38),\n",
       " ('rna isolation', 38),\n",
       " ('respiratory viruse', 38),\n",
       " ('comment', 38),\n",
       " ('protein', 38),\n",
       " ('cell culture ::: method', 38),\n",
       " ('accession numbers ::: materials and method', 38),\n",
       " ('immunoblotting ::: materials and method', 38),\n",
       " ('virus ::: materials and method', 38),\n",
       " ('feline infectious peritoniti', 38),\n",
       " ('diagnóstico', 38),\n",
       " ('fig. 5.', 38),\n",
       " ('references and recommended reading', 38),\n",
       " ('variable', 37),\n",
       " ('cell viability', 37),\n",
       " ('immunocytochemistry', 37),\n",
       " ('viruses and cell line', 37),\n",
       " ('group', 37),\n",
       " ('asthma', 37),\n",
       " ('animal studie', 37),\n",
       " ('multilingual abstract', 37),\n",
       " ('clinical evaluation', 37),\n",
       " ('sds-page and western blot analysi', 37),\n",
       " ('historical perspective', 37),\n",
       " ('anthrax', 37),\n",
       " ('clinical pathology', 37),\n",
       " ('phylogenetic analysis ::: method', 37),\n",
       " ('virus isolation ::: materials and method', 37),\n",
       " ('8. conclusion', 37),\n",
       " ('virus titration ::: materials and method', 37),\n",
       " ('traitement', 37),\n",
       " ('expert opinion', 37),\n",
       " ('parameter', 36),\n",
       " ('clinical outcome', 36),\n",
       " ('funding information', 36),\n",
       " ('virus preparation', 36),\n",
       " ('case 1', 36),\n",
       " ('symptom', 36),\n",
       " ('hiv', 36),\n",
       " ('bacterial strain', 36),\n",
       " ('sequence and phylogenetic analysi', 36),\n",
       " ('data analyse', 36),\n",
       " ('western blot assay', 36),\n",
       " ('histopathology ::: materials and method', 36),\n",
       " ('immunofluorescence assay ::: materials and method', 36),\n",
       " ('d i s c u s s i o n', 36),\n",
       " ('mycobacterium tuberculosi', 36),\n",
       " ('8', 35),\n",
       " ('mathematical model', 35),\n",
       " ('supplementary materials:', 35),\n",
       " ('age', 35),\n",
       " ('culture', 35),\n",
       " ('demographic characteristic', 35),\n",
       " ('clinical data', 35),\n",
       " ('conclusions and future prospect', 35),\n",
       " ('microarray', 35),\n",
       " ('pathogen', 35),\n",
       " ('| introduction', 35),\n",
       " ('immunity', 35),\n",
       " ('salmonellosi', 35),\n",
       " ('severe acute respiratory syndrome (sars)', 35),\n",
       " ('elisa ::: method', 35),\n",
       " ('viruses ::: method', 35),\n",
       " ('nucleic acid extraction ::: materials and method', 35),\n",
       " ('quantitative real-time pcr ::: materials and method', 35),\n",
       " ('13', 34),\n",
       " ('dataset', 34),\n",
       " ('molecular dynamics simulation', 34),\n",
       " ('qrt-pcr', 34),\n",
       " ('drug', 34),\n",
       " ('co-immunoprecipitation', 34),\n",
       " ('availability of supporting data', 34),\n",
       " ('sds-page and western blot', 34),\n",
       " ('j o u r n a l p r e -p r o o f', 34),\n",
       " ('cytokine', 34),\n",
       " ('ebola viru', 34),\n",
       " ('statistical analysis ::: patients and method', 34),\n",
       " ('plaque assay ::: materials and method', 34),\n",
       " ('nucleotide sequence accession numbers ::: materials and method', 34),\n",
       " ('related work', 33),\n",
       " ('protein purification', 33),\n",
       " ('patient and public involvement', 33),\n",
       " ('| d iscuss i on', 33),\n",
       " ('peptide', 33),\n",
       " ('concluding remarks and future perspective', 33),\n",
       " ('histopathological analysi', 33),\n",
       " ('leptospirosi', 33),\n",
       " ('sample collection and processing', 33),\n",
       " ('structure', 33),\n",
       " ('epstein-barr viru', 33),\n",
       " ('cat', 33),\n",
       " ('molecular analysi', 33),\n",
       " ('replication', 33),\n",
       " ('mers-cov', 33),\n",
       " ('investigation', 33),\n",
       " ('■ introduction', 33),\n",
       " ('discusión', 33),\n",
       " ('treatment and prevention', 33),\n",
       " ('bioinformatic analysi', 32),\n",
       " ('laboratory procedure', 32),\n",
       " ('synthesi', 32),\n",
       " ('mortality', 32),\n",
       " ('strengths and limitations of this study', 32),\n",
       " ('8.', 32),\n",
       " ('study procedure', 32),\n",
       " ('availability', 32),\n",
       " ('study setting', 32),\n",
       " ('dengue', 32),\n",
       " ('data and software availability', 32),\n",
       " ('cause', 32),\n",
       " ('antiviral', 32),\n",
       " ('mechanism of action', 32),\n",
       " ('trauma', 32),\n",
       " ('hepatitis c', 32),\n",
       " ('cytotoxicity assay ::: materials and method', 32),\n",
       " ('setting ::: method', 32),\n",
       " ('search strategy ::: method', 32),\n",
       " ('sensitivity analysis ::: result', 32),\n",
       " ('immunofluorescence microscopy ::: materials and method', 32),\n",
       " ('data availability ::: materials and method', 32),\n",
       " ('epidemiología', 32),\n",
       " ('compliance with ethics guideline', 32),\n",
       " ('viral pneumonia', 32),\n",
       " ('name', 31),\n",
       " ('chemicals and reagent', 31),\n",
       " ('| discussion', 31),\n",
       " ('reverse transcription', 31),\n",
       " ('antibody detection', 31),\n",
       " ('limitations of the study', 31),\n",
       " ('rsv', 31),\n",
       " ('conclusions and discussion', 31),\n",
       " ('inflammation', 31),\n",
       " ('in situ hybridization', 31),\n",
       " ('study design and setting', 31),\n",
       " ('nmr spectroscopy', 31),\n",
       " ('dna viruse', 31),\n",
       " ('transparency document', 31),\n",
       " ('toxoplasmosi', 31),\n",
       " ('immunohistochemistry ::: method', 31),\n",
       " ('rt-pcr ::: materials and method', 31),\n",
       " ('2. materials and method', 31),\n",
       " ('5. discussion', 31),\n",
       " ('discussion:', 30),\n",
       " ('hand hygiene', 30),\n",
       " ('subcellular fractionation', 30),\n",
       " ('sample processing', 30),\n",
       " ('cell lines and viruse', 30),\n",
       " ('| introduc ti on', 30),\n",
       " ('sequencing and phylogenetic analysi', 30),\n",
       " ('experimental section', 30),\n",
       " ('imaging', 30),\n",
       " ('genbank accession number', 30),\n",
       " ('analytical ultracentrifugation', 30),\n",
       " ('salmonella', 30),\n",
       " ('immunization of mice', 30),\n",
       " ('emerging infectious disease', 30),\n",
       " ('conclusions and recommendation', 30),\n",
       " ('bacterial disease', 30),\n",
       " ('subjects ::: method', 30),\n",
       " ('western blotting analysis ::: materials and method', 30),\n",
       " ('nucleic acid extraction ::: method', 30),\n",
       " ('disclosure of interest', 30),\n",
       " ('strengths and limitations ::: discussion', 30),\n",
       " ('reporting summary ::: method', 30),\n",
       " ('18', 29),\n",
       " ('21', 29),\n",
       " ('analyse', 29),\n",
       " ('laboratory test', 29),\n",
       " ('literature search', 29),\n",
       " ('sars-cov', 29),\n",
       " ('funding statement', 29),\n",
       " ('follow-up', 29),\n",
       " ('methods and material', 29),\n",
       " ('histological analysi', 29),\n",
       " ('serological assay', 29),\n",
       " ('clinical symptom', 29),\n",
       " ('ferret', 29),\n",
       " ('ethical issue', 29),\n",
       " ('cell proliferation assay', 29),\n",
       " ('primer and probe design', 29),\n",
       " ('sds-page and western blotting', 29),\n",
       " ('aim', 29),\n",
       " ('virus identification', 29),\n",
       " ('viral rna extraction', 29),\n",
       " ('bacteriology', 29),\n",
       " ('genetic', 29),\n",
       " ('retroviruse', 29),\n",
       " ('10.', 29),\n",
       " ('9.', 29),\n",
       " ('financial support', 29),\n",
       " ('statistical methods ::: materials and method', 29),\n",
       " ('plasmids ::: method', 29),\n",
       " ('cell culture and transfection ::: materials and method', 29),\n",
       " ('chemicals ::: materials and method', 29),\n",
       " ('i n t r o d u c t i o n', 29),\n",
       " ('16', 28),\n",
       " ('12', 28),\n",
       " ('22', 28),\n",
       " ('study design and patient', 28),\n",
       " ('incubation period', 28),\n",
       " ('population', 28),\n",
       " ('personal protective equipment', 28),\n",
       " ('sequence data', 28),\n",
       " ('coronaviridae', 28),\n",
       " ('hematology', 28),\n",
       " ('statistical', 28),\n",
       " ('quantitative real-time rt-pcr', 28),\n",
       " ('clinical assessment', 28),\n",
       " ('rna viruse', 28),\n",
       " ('protease inhibitor', 28),\n",
       " ('immune response', 28),\n",
       " ('histology and immunohistochemistry', 28),\n",
       " ('patients and specimen', 28),\n",
       " ('yellow fever', 28),\n",
       " ('rabies viru', 28),\n",
       " ('avian influenza', 28),\n",
       " ('hepatitis c viru', 28),\n",
       " ('in vitro transcription and translation', 28),\n",
       " ('cells and viruses. ::: materials and method', 28),\n",
       " ('samples ::: materials and method', 28),\n",
       " ('1. background', 28),\n",
       " ('laboratory methods ::: method', 28),\n",
       " ('virus infection ::: materials and method', 28),\n",
       " ('indirect immunofluorescence assay ::: materials and method', 28),\n",
       " ('ethical statement ::: materials and method', 28),\n",
       " ('flow cytometry analysis ::: materials and method', 28),\n",
       " ('■ conclusion', 28),\n",
       " ('manifestaciones clínica', 28),\n",
       " ('main text', 27),\n",
       " ('executive summary', 27),\n",
       " ('rt-qpcr', 27),\n",
       " ('3.2.', 27),\n",
       " ('hemagglutination assay', 27),\n",
       " ('flaviviruse', 27),\n",
       " ('virus and cell culture', 27),\n",
       " ('adjuvant', 27),\n",
       " ('study design and population', 27),\n",
       " ('dengue viru', 27),\n",
       " ('immunohistochemistry (ihc)', 27),\n",
       " ('animals and experimental design', 27),\n",
       " ('hantaviru', 27),\n",
       " ('intracellular cytokine staining', 27),\n",
       " ('virus purification', 27),\n",
       " ('lessons learned', 27),\n",
       " ('incidence', 27),\n",
       " ('enteroviruse', 27),\n",
       " ('definitions ::: method', 27),\n",
       " ('histology ::: materials and method', 27),\n",
       " ('transfection ::: materials and method', 27),\n",
       " ('enzyme-linked immunosorbent assay (elisa) ::: materials and method', 27),\n",
       " ('luciferase assay ::: materials and method', 27),\n",
       " ('etiología', 27),\n",
       " ('parasitic infection', 27),\n",
       " ('resultado', 27),\n",
       " ('numerical simulation', 26),\n",
       " ('model validation', 26),\n",
       " ('eligibility criteria', 26),\n",
       " ('adverse event', 26),\n",
       " ('strain', 26),\n",
       " ('experimental protocol', 26),\n",
       " ('cost', 26),\n",
       " ('antiviral activity assay', 26),\n",
       " ('cytotoxicity', 26),\n",
       " ('structure determination', 26),\n",
       " ('sensitivity', 26),\n",
       " ('cell and viru', 26),\n",
       " ('research', 26),\n",
       " ('genotyping', 26),\n",
       " ('time-of-addition assay', 26),\n",
       " ('hemagglutination inhibition assay', 26),\n",
       " ('the way forward', 26),\n",
       " ('smallpox', 26),\n",
       " ('dog', 26),\n",
       " ('diet', 26),\n",
       " ('housing', 26),\n",
       " ('environmental factor', 26),\n",
       " ('electrophoretic mobility shift assay', 26),\n",
       " ('polymerase chain reaction (pcr)', 26),\n",
       " ('summary and perspective', 26),\n",
       " ('clinical examination', 26),\n",
       " ('cells ::: method', 26),\n",
       " ('western blot ::: method', 26),\n",
       " ('transmission electron microscopy ::: materials and method', 26),\n",
       " ('microarray analysis ::: materials and method', 26),\n",
       " ('virus and cells ::: materials and method', 26),\n",
       " ('3. results and discussion', 26),\n",
       " ('nucleotide sequence accession number. ::: genome announcement', 26),\n",
       " ('nutrition', 26),\n",
       " ('brucellosi', 26),\n",
       " ('parasitic disease', 26),\n",
       " ('surgery', 26),\n",
       " ('indication', 26),\n",
       " ('17', 25),\n",
       " ('model description', 25),\n",
       " ('2', 25),\n",
       " ('parameter estimation', 25),\n",
       " ('in vitro transcription', 25),\n",
       " ('specie', 25),\n",
       " ('immunostaining', 25),\n",
       " ('sequence alignment', 25),\n",
       " ('patient population', 25),\n",
       " ('paramyxoviridae', 25),\n",
       " ('humoral immune response', 25),\n",
       " ('methods and finding', 25),\n",
       " ('descriptive statistic', 25),\n",
       " ('neutrophil', 25),\n",
       " ('herpesviridae', 25),\n",
       " ('concluding remarks and future direction', 25),\n",
       " ('antimicrobial resistance', 25),\n",
       " ('seasonality', 25),\n",
       " ('pig', 25),\n",
       " ('histopathological examination', 25),\n",
       " ('neutralization test', 25),\n",
       " ('method detail', 25),\n",
       " ('diagnostic testing', 25),\n",
       " ('liposome', 25),\n",
       " ('materials and reagent', 25),\n",
       " ('streptococcus pneumoniae', 25),\n",
       " ('samples ::: method', 25),\n",
       " ('measures ::: method', 25),\n",
       " ('animal experiments ::: materials and method', 25),\n",
       " ('quantitative rt-pcr ::: materials and method', 25),\n",
       " ('study area ::: materials and method', 25),\n",
       " ('flow cytometric analysis ::: materials and method', 25),\n",
       " ('immunoprecipitation ::: materials and method', 25),\n",
       " ('ethics statement. ::: materials and method', 25),\n",
       " ('hepatitis b viru', 25),\n",
       " ('respiratory system', 25),\n",
       " ('bacterial pneumonia', 25),\n",
       " ('data and code availability', 24),\n",
       " ('simulation result', 24),\n",
       " ('quality assessment', 24),\n",
       " ('primer name', 24),\n",
       " ('13.', 24),\n",
       " ('zika viru', 24),\n",
       " ('conclusion and discussion', 24),\n",
       " ('conclusions and implication', 24),\n",
       " ('study sample', 24),\n",
       " ('study characteristic', 24),\n",
       " ('risk assessment', 24),\n",
       " ('contact for reagent and resource sharing', 24),\n",
       " ('monitoring', 24),\n",
       " ('genome organization', 24),\n",
       " ('environment', 24),\n",
       " ('probiotic', 24),\n",
       " ('autophagy', 24),\n",
       " ('subunit vaccine', 24),\n",
       " ('dendritic cell', 24),\n",
       " ('participant characteristic', 24),\n",
       " ('database', 24),\n",
       " ('study protocol', 24),\n",
       " ('cells and reagent', 24),\n",
       " ('antibody response', 24),\n",
       " ('co-infection', 24),\n",
       " ('clinical trial', 24),\n",
       " ('helicobacter pylori', 24),\n",
       " ('human', 24),\n",
       " ('viruses and cell culture', 24),\n",
       " ('astroviru', 24),\n",
       " ('conclusion and outlook', 24),\n",
       " ('resumen', 24),\n",
       " ('education', 24),\n",
       " ('antigen', 24),\n",
       " ('cystic fibrosi', 24),\n",
       " ('fluid therapy', 24),\n",
       " ('prevalence', 24),\n",
       " ('radiology', 24),\n",
       " ('preparation', 24),\n",
       " ('listeria monocytogene', 24),\n",
       " ('résumé', 24),\n",
       " ('viruses and cells ::: method', 24),\n",
       " ('subjects ::: materials and method', 24),\n",
       " ('ethics ::: materials and method', 24),\n",
       " ('real-time rt-pcr ::: materials and method', 24),\n",
       " ('2.9. statistical analysis ::: 2. materials and method', 24),\n",
       " ('conflict of interest declaration', 24),\n",
       " ('diagnostic imaging', 24),\n",
       " ('author manuscript', 24),\n",
       " ('27', 23),\n",
       " ('data and method', 23),\n",
       " ('treatment and prognosi', 23),\n",
       " ('patient selection', 23),\n",
       " ('data collection and processing', 23),\n",
       " ('baseline characteristic', 23),\n",
       " ('contribution', 23),\n",
       " ('model formulation', 23),\n",
       " ('rna extraction and rt-pcr', 23),\n",
       " ('circular dichroism spectroscopy', 23),\n",
       " ('flaviviridae', 23),\n",
       " ('respiratory syncytial virus (rsv)', 23),\n",
       " ('introduction and background', 23),\n",
       " ('ack n owled g em ent', 23),\n",
       " ('data management and analysi', 23),\n",
       " ('indirect elisa', 23),\n",
       " ('macrophage', 23),\n",
       " ('radiography', 23),\n",
       " ('rna preparation', 23),\n",
       " ('viral load', 23),\n",
       " ('cell culture and virus infection', 23),\n",
       " ('genome sequencing', 23),\n",
       " ('gene expression analysi', 23),\n",
       " ('respiratory disease', 23),\n",
       " ('future research', 23),\n",
       " ('clinical disease', 23),\n",
       " ('the future', 23),\n",
       " ('real-time quantitative pcr', 23),\n",
       " ('diagnosis and treatment', 23),\n",
       " ('toll-like receptor', 23),\n",
       " ('respiratory infection', 23),\n",
       " ('microneutralization assay', 23),\n",
       " ('laboratory investigation', 23),\n",
       " ('cardiovascular system', 23),\n",
       " ('anti-inflammatory activity', 23),\n",
       " ('rat', 23),\n",
       " ('circular dichroism', 23),\n",
       " ('rhinoviruse', 23),\n",
       " ('parainfluenza viru', 23),\n",
       " ('sequence analysis ::: method', 23),\n",
       " ('quantitative pcr ::: materials and method', 23),\n",
       " ('virus ::: method', 23),\n",
       " ('3. conclusion', 23),\n",
       " ('experimental design ::: method', 23),\n",
       " ('conclusión', 23),\n",
       " ('acute bronchiti', 23),\n",
       " ('diagnostic evaluation', 23),\n",
       " (\"déclaration d'intérêt\", 23),\n",
       " ('measles viru', 23),\n",
       " ('mycoplasma pneumoniae', 23),\n",
       " ('fungal disease', 23),\n",
       " ('cell cycle analysi', 22),\n",
       " ('clinical implication', 22),\n",
       " ('v. conclusion', 22),\n",
       " ('sample size calculation', 22),\n",
       " ('pharmacokinetic', 22),\n",
       " ('observation', 22),\n",
       " ('immunofluorescence and confocal microscopy', 22),\n",
       " ('picornaviridae', 22),\n",
       " ('apoptosi', 22),\n",
       " ('evaluation', 22),\n",
       " ('sampling procedure', 22),\n",
       " ('indirect immunofluorescence microscopy', 22),\n",
       " ('real-time quantitative rt-pcr', 22),\n",
       " ('laboratory analysi', 22),\n",
       " ('morphology', 22),\n",
       " ('cells, viruses, and reagent', 22),\n",
       " ('sequence', 22),\n",
       " ('serological test', 22),\n",
       " ('primers and probe', 22),\n",
       " ('viral culture', 22),\n",
       " ('final remark', 22),\n",
       " ('declaration of conflicting interest', 22),\n",
       " ('viral', 22),\n",
       " ('immunology', 22),\n",
       " ('crystallization and data collection', 22),\n",
       " ('antibacterial activity', 22),\n",
       " ('viruses and infection', 22),\n",
       " ('supplemental data', 22),\n",
       " ('plague', 22),\n",
       " ('toxicity', 22),\n",
       " ('case study', 22),\n",
       " ('financial & competing interests disclosure', 22),\n",
       " ('therapie', 22),\n",
       " ('vaccine development', 22),\n",
       " ('12.', 22),\n",
       " ('hepatitis viruse', 22),\n",
       " ('commentary', 22),\n",
       " ('sepsi', 22),\n",
       " ('cholera', 22),\n",
       " ('cryptosporidiosi', 22),\n",
       " ('laboratory testing ::: method', 22),\n",
       " ('design ::: method', 22),\n",
       " ('rna extraction ::: method', 22),\n",
       " ('study limitations ::: discussion', 22),\n",
       " ('sampling ::: method', 22),\n",
       " ('fluorescence microscopy ::: materials and method', 22),\n",
       " ('sampling ::: materials and method', 22),\n",
       " ('clinical characteristics ::: result', 22),\n",
       " ('antibodies and reagents ::: materials and method', 22),\n",
       " ('rna interference ::: materials and method', 22),\n",
       " ...]"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted(sections.items(), key=lambda x: x[1], reverse=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "52097"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "class Paper:\n",
    "    def __init__(self, )"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
